Millendo Raises $62m, Licenses AstraZeneca Drug
This article was originally published in Scrip
Executive Summary
Millendo Therapeutics raised $62m in a Series B round led by New Enterprise Associates and the endocrine disorder-focused biotech firm licensed a polycystic ovary syndrome (PCOS) drug candidate from AstraZeneca PLC in a deal that will widen the company's focus.
You may also be interested in...
Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
GSK Spin-Out NeRRe Raises £23m For NK Antagonists
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Need a specific report? 1000+ reports available Buy Reports